CA
NZ
UK
AU
IND
US
JPMorgan Chase & Co. filed an amended Schedule 13G with the SEC on November 5, 2026, disclosing beneficial ownership of 8,022,860 shares of Allegro MicroSystems, Inc. common stock as of October 30, 2026.
JPMorgan Chase & Co. filed Amendment No. 2 to a Schedule 13G with the SEC on November 5, 2026, disclosing its beneficial ownership of Class A Common Stock of Levi Strauss & Co. as of October 30, 2026.
Several mechanisms can drive such a move; this is general context, not a confirmed cause. First, a pending combination with Aaron's and CCF Holdings changes the expectedBusinessmix and share count, and arbitrage or event funds may trade the setup. Second, a lease-to-own and point-of-sale …
Clinical data are the usual driver for a biotech. A randomized, placebo-controlled win in a rare blood disease lifts the probability of approval, brings a Phase 3 trial into view, and raises partnering interest. The company plans to start a Phase 3 quarterly dosing …
No single catalyst identified in the material reviewed, and the third quarter figures were not confirmed. General context: a restaurant stock that has fallen to the low end of its range can rebound sharply when short sellers cover, when earnings expectations are cut low …
No single catalyst identified beyond the October 29, 2026 results, and consensus figures were not confirmed. The swing from a net loss of USD 117.938 million to a profit of USD 18.142 million is the clearest change, and a turnaround from a loss can …
The catalyst was anEarningsbeat with fourth quarter profit guidance above consensus, tied to AI-driven delivery and productivity gains. Published coverage on October 30, 2026 described the shares as rocketing higher. General context: a company whose margins widen while revenue grows 9.7% can see estimates …
The company release points to pivotal program data as the main driver, though the price move cannot be tied to one headline. In the PiNACLE trial of ronde-cel in third-line and later large B-cell lymphoma, 44 patients were efficacy-evaluable. The overall response rate was …
The rationale is governance and strategic change. Vishal Garg says he was removed as CEO at the August 3, 2026 board meeting, and his group claims written consents from over 51% of voting shares to remove five of eight directors. The company has not …
The rationale is an earnings beat on a low expectation base plus cash generation. Free cash flow of about USD 121 million more than doubled year over year, and the full-year target is at least USD 250 million including legal payments. At the Acima …
Please wait processing your request...